1. Gene expression and copy number profiling of follicular lymphoma biopsies from patients treated with first-line rituximab without chemotherapy.
- Author
-
Leich, E., Brodtkorb, Marianne, Schmidt, T., Altenbuchinger, M., Lingjærde, Ole Christian, Lockmer, S., Holte, H., Nedeva, T., Grieb, T., Sander, B., Sundström, C., Spang, R., Kimby, E., and Rosenwald, A.
- Subjects
- *
FOLLICULAR lymphoma , *RITUXIMAB , *GENE expression , *CANCER chemotherapy , *LOGISTIC regression analysis - Abstract
The Nordic Lymphoma Study Group has performed two randomized clinical trials with chemotherapy-free first-line treatment (rituximab +/- interferon) in follicular lymphoma (FL), with 73% of patients alive and 38% without any need of chemotherapy after 10.6 years median follow-up. In order to identify predictive markers, that may also serve as therapeutic targets, gene expression- and copy number profiles were obtained from 97 FL patients using whole genome microarrays. Copy number alterations (CNAs) were identified, e.g. by GISTIC. Cox Lasso Regression and Lasso logistic regression were used to determine molecular features predictive of time to next therapy (TTNT). A few molecular changes were associated with TTNT (e.g. increased expression of INPP5B, gains in 12q23/q24), but were not significant after adjusting for multiple testing. Our findings suggest that there are no strong determinants of patient outcome with respect to GE data and CNAs in FL patients treated with a chemotherapy-free regimen (i.e. rituximab +/– interferon). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF